PRESS RELEASE Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference Mont-Saint-Guibert, Belgium – September 2, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development
Featured Image for General Atomics Aeronautical Systems, Inc. LEEUWARDEN, Netherlands, Sept. 02, 2021 (GLOBE NEWSWIRE) — In cooperation with the UK and Netherlands airspace authorities, the Royal Air Force, and the Royal Netherlands Air Force (RNLAF), General Atomics Aeronautical Systems,
New webinar series: Administrative Violence and the Tai Ji Men Case A Webinar on the Fabricated Tai Ji Men Case in Taiwan LOS ANGELES, Sept. 02, 2021 (GLOBE NEWSWIRE) — With the Delta variant raging as well as wars and
The Luxury today announced that the development of its new venture, Luxandia is currently at 40%, with a full launch scheduled for late Spring 2022. Luxandia will be a global virtual reality space dedicated to the online luxury industry, presenting
OKEx continues its commitment to the advancement of the crypto industry and decentralized finance with the launch of DeFi Hub VICTORIA, Seychelles, Sept. 02, 2021 (GLOBE NEWSWIRE) — OKEx (www.okex.com), a leading global cryptocurrency spot and derivatives exchange, today announced
Join bp’s Bernard Looney, Anglo American’s Mark Cutifani and Shell’s Maarten Wetselaar as event assesses impact of energy transition on natural resources sector LONDON/HOUSTON/SINGAPORE, Sept. 02, 2021 (GLOBE NEWSWIRE) — This year will prove pivotal for the energy sector. But
September 2, 2021 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the sale of the Domestic Appliances business to Hillhouse Investment, a global investment firm. The
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from Phase 3 CHELATE clinical trial — TETA 4-HCl previously granted Orphan Drug
